Teva Pharmaceutical Industries has been granted a patent for crystalline polymorphs of Rigosertib Sodium, along with processes for their preparation and pharmaceutical compositions. The patent includes a specific crystalline form designated as Form A, characterized by unique data points. GlobalData’s report on Teva Pharmaceutical Industries gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Teva Pharmaceutical Industries, Cancer treatment biomarkers was a key innovation area identified from patents. Teva Pharmaceutical Industries's grant share as of May 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
Crystalline form of rigosertib sodium designated as form a
A recently granted patent (Publication Number: US11981624B2) discloses a crystalline form of Rigosertib Sodium known as Form A. This form is characterized by specific data points including XRPD patterns, solid-state 13C NMR spectra, and chemical shift absolute differences. The patent also covers the crystalline form's solvates, such as ethanol or isopropanol solvates, and its composition containing a certain percentage of water. Additionally, the patent includes claims related to pharmaceutical compositions, formulations, processes for preparation, and medicaments involving the crystalline Form A of Rigosertib Sodium.
Furthermore, the patent details a process for preparing Rigosertib Sodium Form A, involving crystallization in a mixture of ethanol or isopropanol in water. The process includes specific steps such as heating, cooling, isolating the Form A, and combining it with pharmaceutically acceptable excipients. Various volume ratios of solvents, temperature ranges, and durations are specified in the process for obtaining the desired crystalline form. The patent also emphasizes the importance of washing and drying steps under reduced pressure to ensure the quality of the final product. Overall, the patent covers a comprehensive range of claims related to the unique crystalline form of Rigosertib Sodium and its pharmaceutical applications.
To know more about GlobalData’s detailed insights on Teva Pharmaceutical Industries, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
